Assessing the role of Mac-2 binding protein glycosylation isomer in the management of patients with chronic hepatitis B

Table 1 Baseline characteristics of 346 study participants, n (%)/means ± SE/median (min-max)

Variable	CHB patients (n = 346)
Sex
Male	206 (59.5)
Female	140 (40.5)
Age (years)	42.6 ± 0.65
Fibrosis stage (n)
F0	37
F1	83
F2	105
F3	48
F4	73
Fibroscan (kPa)	7.7 (0.4-46.5)
Platelet count (109/L)	213 (49-394)
AST (µl/L)	29 (12.9-235.6)
ALT (µl/L)	31.9 (6.2-191.8)
Hemoglobin (g/L)	14.5 (4.6-18.4)
WBC (109/L)	6.6 (3.6-15.8)
M2BPGi (C.O.I)	1.02 (0.19-12.9)
FIB-4	1.0 (0.32-11.3)
APRI	0.38 (0.11-6.93)

CHB: Chronic hepatitis B; AST: Aspartate transaminase; ALT: Alanine transaminase; WBC: White blood counts; C.O.I: Cut-off index; FIB-4: Fibrosis-4 index; M2BPGi: Mac-2 binding protein glycosylated isomer; APRI: Aspartate transaminase to platelet ratio index.